Call IMI2-2020-20-01 for the development of early diagnostic tools and personalized treatment of psoriatic arthritis
Early diagnosis and personalized treatment for psoriatic arthritis: call IMI2-2020-20-01
What we can do, as an SME partner:
For the call IMI2-2020-20-01, we can use our expertise in microfluidic instrumentation and flow management to help you develop a lab-on-a-chip platform for psoriatic arthritis (PsA) early detection or an organ-on-a-chip platform (for example, bone-on-a-chip) to better understand disease progression and identify new treatments. Patient cells can be used in these models to enable personalized treatment.
Specifically, the MIC can:
- Develop an innovative microfluidic setup to inject patient samples into lab-on-chip devices, for early stage detection of biomarkers during a simple doctor appointment
- Propose a user-friendly organ-on-chip platform to recreate a bone model, study psoriatic arthritis (PsA) progression, and test new drugs
- Provide a robust solution for the perfusion of your microfluidic device and, optimize the flow inside your chip
What can microfluidics do for the early diagnostic and personalized treatment of psoriatic arthritis ?
The use of microfluidics will allow you to meet the specific objectives of the call IMI2-2020-21-01 about psoriatic arthritis diagnostic and treatment:
- To enable rheumatologists, dermatologists, and general practitioners an early diagnosis of psoriatic arthritis (PsA) in patients with PsO and other rheumatic disorders and to identify early patients at risk of progression to psoriatic arthritis (PsA) to enable earlier interventions and possibly prevent psoriatic arthritis (PsA) development;
⇒ Labs-on-chip are perfectly adapted for early diagnosis of PsA. Working at the microscale decreases the volume of sample needed and may increase the sensitivity of the test. Labs-on-chip are also perfectly suitable for point-of-care analysis, thus allowing easy and quick testing of patients at the doctor’s office instead of cumbersome lab analysis.
- To define the factors that predict disease progression in psoriatic arthritis (PsA) patients, including early prediction of bone/joint damages, leading to the development of more adapted treatment strategies;
⇒ Thanks to microfluidics, developing very relevant bone or joint models with organ-on-chip technology is possible. These models, avoiding the use of animals, can be used to study the disease progression and test new treatments.
- To develop rational and personalized treatment strategies (e.g., select the optimal first-line or second-line treatment based on patient characteristics) with optimized outcomes in psoriatic arthritis (PsA) patients and reduce the disease burden.
⇒ Microfluidics is a technology of choice for personalized medicine. For example, a bone-on-chip model can be designed using patient cells to test different treatments and choose the most efficient.
How can the MIC help in your project?
The MIC already brought its microfluidics expertise into many research projects:
H2020-NMBP-TR-IND-2020
Microfluidic platform to study the interaction of cancer cells with lymphatic tissue
H2020-LC-GD-2020-3
Toxicology assessment of pharmaceutical products on a placenta-on-chip model
